Clinical TrialID 7746
A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
NCT02057302
Dyslipidemia
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Formula: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7746
- Evidence Id
- 7746
- Core Evidence Id
- 7746
- Source Clinical Trial Id
- 7741
- Herb2 Clinical Trial Id
- HBCT007741
- Nct Id
- NCT02057302
- Title
- A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
- Status
- Completed
- Phase
- Phase 4
- Study Result
- No
- Study Condition
- Dyslipidemia
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, CARE_PROVIDER)|Primary Purpose: TREATMENT
- Intervention
- DRUG: Xuezhikang capsule
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 2400
- Outcome Measure
- Blood samples were drawn were detected,including TC,TG,LDL-C and HDL-C, the detect the change from baseline to the 8th week
- Sponsor Collaborator
- China Academy of Chinese Medical Sciences
- Funded By
- OTHER
- Location
- Other Id
- 2008ZX09202-007
- Start Date
- 2010-03
- Primary Completion Date
- 2012-12
- Completion Date
- First Posted
- 2014-02-07
- Results First Posted
- Last Update Posted
- 2014-02-07
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT02057302
- Title Cn
- Title En
- A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia
- Bilingual Status
- semi_complete